Meeting
2019 ASCO Annual Meeting
Reassignment of HER2 status for subgroups of breast cancer according to the 2018 updated American Society of Clinical Oncology and College of American Pathologists guidelines: The impact of combined immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) reflex testing in a large national reference laboratory.
Authors
Katherine Geiersbach
Mayo Clinic, Rochester, MN
Katherine Geiersbach , Reid G. Meyer , Sara M. Kloft-Nelson , Darlene L. Knutson , Ryan A. Knudson , William R. Sukov , Rhett P. Ketterling , Patricia T. Greipp , Robert B. Jenkins
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Developmental Therapeutics and Tumor Biology (Nonimmuno)
Track
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology
Sub Track
Tissue-Based Biomarkers
Citation
J Clin Oncol 37, 2019 (suppl; abstr 3144)
DOI
10.1200/JCO.2019.37.15_suppl.3144
Abstract #
3144
Poster Bd #
136
Abstract Disclosures
Similar Posters
Poster
2016 ASCO Annual Meeting
HER2 gene amplification testing by fluorescence in situ hybridization (FISH): Comparison of the ASCO-CAP guidelines with FISH scores used for enrollment in breast cancer international research group (BCIRG) clinical trials.
First Author: Michael F. Press
Poster
2023 ASCO Annual Meeting
The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab.
First Author: Tarek Mohamed Ahmed Abdel-Fatah
Poster
2023 ASCO Annual Meeting
Evolution of HER2 scores after neoadjuvant systemic therapy in breast cancer.
First Author: Esther G Chong
Poster
2023 ASCO Annual Meeting
AI-based HER2-low IHC scoring in breast cancer across multiple sites, clones, and scanners.
First Author: Patrick Frey